What defines an orphan drug and which incentives are offered?

Prepare for the Drug Discovery and Healthcare Systems Test. Access flashcards and multiple-choice questions with hints and explanations. Ace your exam with our comprehensive resources!

Orphan drugs are medicines developed for rare diseases, where the patient population is small and the market alone may not support research and development. To encourage this work, regulators offer incentives that reduce the burden of bringing these therapies to market. The incentives include market exclusivity (protecting the drug from competition for the specific orphan indication for a defined period), tax credits for qualifying clinical research, grant funding to support development costs, and protocol assistance or scientific advice to help design studies that meet regulatory standards. This combination of benefits is why the option listing development for rare diseases with incentives such as market exclusivity, tax credits, grant funding, and protocol assistance best fits the concept. The other descriptions don’t align with how orphan designation works: common diseases with exclusivity, no clinical benefit with penalties, or pediatric-exclusive terms don’t capture the rare-disease focus and its incentives.